Quality of life in patients with relapsing multiple sclerosis taking intramuscular interferon beta-1a (Avonex®)

被引：0
作者：
Hyde, R.
Rudick, R. A.
Foulds, P.
You, X.
机构：
[1] Biogen Idec Int, Zug, Switzerland
[2] Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH USA
[3] Biogen Idec Inc, Cambridge, MA 02142 USA
来源：
JOURNAL OF NEUROLOGY | 2008年 / 255卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P455
引用
收藏
页码：113 / 113
页数：1
相关论文
共 50 条
  • [21] A study of the effect of gender on interferon beta-1a (Avonex® 30 mcg) treatment in patients with multiple sclerosis
    Munschauer, FE
    Herndon, R
    Sandrock, AW
    Tsao, E
    Berkhoff, JE
    Stubbendick, A
    MULTIPLE SCLEROSIS, 2005, 11 : S78 - S78
  • [22] Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis
    Rudick, RA
    Goodkin, DE
    Jacobs, LD
    Cookfair, DL
    Herndon, RM
    Richert, JR
    Salazar, AM
    Fischer, JS
    Granger, CV
    Simon, JH
    Alam, JJ
    Simonian, NA
    Campion, MK
    Bartoszak, DM
    Bourdette, DN
    Braiman, J
    Brownscheidle, CM
    Coats, ME
    Cohan, SL
    Dougherty, DS
    Kinkel, RP
    Mass, MK
    Munschauer, FE
    Priore, RL
    Pullicino, PM
    Scherokman, BJ
    WeistockGuttman, B
    Whitham, RH
    NEUROLOGY, 1997, 49 (02) : 358 - 363
  • [23] Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
    Vazquez Gomez, Lazaro Aurelio
    Hidalgo Mesa, Carlos
    Broche Perez, Yunier
    Valdes Morales, Yanet
    MEDISUR-REVISTA DE CIENCIAS MEDICAS DE CIENFUEGOS, 2022, 20 (05): : 825 - 833
  • [24] Combination therapy of interferon beta-1a with alefacept for active relapsing multiple sclerosis patients
    Weinstock-Guttman, B
    Ramanathan, M
    Zivadinov, R
    Munschauer, FE
    MULTIPLE SCLEROSIS, 2005, 11 : S79 - S79
  • [25] Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis
    Rudick, RA
    Goodkin, DE
    Jacobs, LD
    Cookfair, DL
    Herndon, RM
    Richert, JR
    Salazar, AM
    Fischer, JS
    Granger, CV
    Simon, JH
    Alam, JJ
    Simonian, NA
    Campion, MK
    Bartoszak, DM
    Bourdette, DN
    Braiman, J
    Brownscheidle, CM
    Coats, ME
    Cohan, SL
    Dougherty, DS
    Kinkel, RP
    Mass, MK
    Munschauer, FE
    Priore, RL
    Pullicino, PM
    Scherokman, BJ
    Weistock-Guttman, B
    Whitham, RH
    NEUROLOGY, 2001, 57 (12) : S25 - S30
  • [26] Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
    Kappos, L.
    Wiendl, H.
    Selmaj, K.
    Arnold, D. L.
    Havrdova, E.
    Boyko, A.
    Kaufman, M.
    Rose, J.
    Greenberg, S.
    Sweetser, M.
    Riester, K.
    O'Neill, G.
    Elkins, J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (15) : 1418 - 1428
  • [27] Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: A double blind randomized clinical trial
    Nafissi, Shahriar
    Azimi, Amirreza
    Amini-Harandi, Ali
    Salami, Shiva
    Shahkarami, Mohammad Amir
    Heshmat, Ramin
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2012, 114 (07) : 986 - 989
  • [28] Estimating Net Health Benefits of Intramuscular Interferon Beta-1a and Fingolimod in Treating Patients with Relapsing-Remitting Multiple Sclerosis
    Szabo, Shelagh
    Dembek, Carole
    Moore, Peter
    White, Leigh Ann
    Wijaya, Hardy
    Levy, Adrian
    NEUROLOGY, 2012, 78
  • [29] Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis (vol 39, pg 285, 1996)
    Jacobs, LD
    ANNALS OF NEUROLOGY, 1996, 40 (03) : 480 - 480
  • [30] ESTIMATING NET HEALTH BENEFITS OF INTRAMUSCULAR INTERFERON BETA-1A AND FINGOLIMOD IN TREATING PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Szabo, S. M.
    Dembek, C.
    Moore, P.
    White, L. A.
    Wijaya, H.
    Levy, A. R.
    VALUE IN HEALTH, 2011, 14 (07) : A317 - A317
12345